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ABSTRACT
Substantial changes have occurred in the nutritional management of many diseases in the last twenty 
years. Introduction of standards, clinical review and implementation of evidence based practice led to 
re-evaluation of some established dietary interventions. The most common form of osteoporosis is the 
primary osteoporosis, which is the result of the bone loss and deterioration of bone structure, as people 
age. Bone loss and osteoporosis can be prevented through adequate nutrition, physical activity, and, if 
necessary, appropriate treatment. This review will focus on nutritional and clinical aspects of bone tissue 
homeostasis, with references to physiological and pathophysiological processes.
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INTRODUCTION
Substantial changes have occurred in the nutri-
tional management of many diseases in the last 
twenty years. Th e changes were accompanied with 
the increase of awareness of their signifi cance and 
have also occurred in the nutritional management of 
bone tissue diseases. Many changes in clinical nutri-
tion have been associated with the introduction of 
standards, clinical review and implementation of 
practice based on evidence, which led to re-evalua-
tion of some established dietary interventions using 
the hierarchy of evidence approach. It is necessary to 
ensure the effi  cacy of nutritional interventions with-
out undesirable side eff ects, and to systematically 
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evaluate clinical practice, as well as to modify the 
practice in light of current research (1).
Osteoporosis is systemic skeletal disease and the 
most common metabolic disease of bones, charac-
terized by reduced bone tissue mass and impaired 
microarchitecture. Consequently, the risk of frac-
tures is increased, which results in increased morbid-
ity and mortality, especially in the older population. 
Given that osteoporosis is a disease related to age, it 
is also related to low bone mineral density (BMD), 
microarchitectural bone deterioration, bone tissue 
fragility, and increased risk of fracture (2).
Osteoporosis is one of major public health problems 
in developed countries, with tendency to increase 
in relation to aging of population. Osteoporosis 
is more common in women, aff ecting 22 million 
women age >50  years in Europe, or 22% of the 
female population. At the age of 50 years, the life-
time probability of hip fracture is 7-25%, and it 
accounts for almost 50% of major fractures among 
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European women (3). Between 2000 and 2050, the 
share of world population aged >60 years is foreseen 
to double, from 11% to 22%. Th e absolute number 
of people aged ≥60 years is expected to increase from 
605 million to 2 billion by 2050, while the number 
of people aged ≥80 years will quadruple to 395 mil-
lion by 2050 (4).
Th e risk of osteoporotic fracture increases signifi -
cantly during the seventh decade of life, and the 
prevalence of sarcopenia increases signifi cantly with 
age, which also contributes to the risk of fracture. 
Th erefore, preventive therapy and adequate nutri-
tion are extremely important for a person with 
increased risk of fractures (5).
BONE TISSUE HOMEOSTASIS
Bone tissue is the major supporting tissue in human 
body. Bone mass is formed in childhood and youth, 
and the process is active until thirty years of age 
when it reaches its maximum. Th en it decreases with 
age, signifi cantly more in women than in men, and 
it is determined largely by genetic factors (6). Low 
BMD may be the result of reduced bone building 
in childhood or puberty, or increased bone loss in 
later life. During a lifetime, the bone is constantly 
remodeled. It degrades when it is old, or bone struc-
ture is less viable, or when damaged by micro-frac-
tures, and it is replaced by new and more resistant 
bone structure, which is especially important at 
the point of increased stress (7). Depending on the 
part of the skeleton, hereditary factors determine 
50-85% of diff erences in bone mass. Among the 
set of genes that aff ect peak bone mass (PBM), it 
seems that the genes for collagen type 1 and vitamin 
D receptor have the major role (6). Th e other fac-
tors that cause low PBM include insuffi  cient intake 
of calcium in childhood, low body weight, poor 
nutrition, delayed puberty, and insuffi  cient physical 
activity (8,9).
Optimal treatment of fractures or bone defects 
requires the knowledge of complex cellular interac-
tions involved in healing and remodeling of bone 
tissue. In addition, osteoclasts are important in 
this process because they play a key role in normal 
bone turnover and facilitate bone regeneration (10). 
Osteogenesis or ossifi cation is a process in which 
bone tissue is formed. In the formation of bone 
tissue, osteogenic cells diff erentiate and develop 
into osteoblasts. According to osteoinduction prin-
ciple, osteoblasts and formed bone tissue require 
corresponding base, a porous structure that enables 
three-dimensional penetration of bone tissue into 
the depth (11).
In general, osteogenesis involves two processes: 
a) the process of building bone tissue (osteoproduc-
tion) and b) degradation of bone tissue (osteo-re-
absorption) (12). Building and degradation of bone 
tissue occur simultaneously. Synergistically and 
physiologically they are balanced processes, since 
both aff ect the formation and maintenance of the 
tissue homeostasis of skeletal system in accordance 
with functional requirements (Wolff ’s Law on Bone 
Transformation). During a lifespan, the skeletal sys-
tem is subjected to continuous transformation in 
order to maintain its optimal function as the main 
supporting system in an adult organism. Th e bal-
ance between the processes of formation and deg-
radation of bone tissue is variable and manifested 
in physiological and pathological processes. Th e 
disruption of physiological balance between these 
two processes is manifested in pathological osteo-
genesis where homeostasis of bone tissue is inter-
rupted, regardless of the cause (osteoarthritis or 
osteoporosis). During embryonic development and 
growth of skeletal system, osteoproduction domi-
nates and bone tissue mass is increased. Anatomical 
norm, i.e. the form and size of bones, is achieved in 
the formation phase during which the intensity of 
osteoproduction declines. Signifi cant regeneration 
power of bone tissue appears in the healing process 
of bone fracture (13).
During embryonic development, the bones are 
developed from embryonic connective tissue. Th e 
organization and morphology of skeleton during 
the development are determined by a series of pro-
grammed and induced processes. Th e bones achieve 
normal anatomical size and form around the age of 
twenty. At that time, the proliferation of chondro-
cytes stops in the epiphyseal cartilage area which 
is closer to epiphysis, and the ossifi cation on the 
diaphyseal side continues until disappearance of 
the epiphyseal cartilage. Th is results in synostosis 
between epiphysis and diaphysis and it marks cessa-
tion of bone growth in length. After the end of bone 
formation, life-long remodeling begins. Remodeling 
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is the response of bone tissue to biomechanical and 
metabolic demands of organism in order to main-
tain the homeostasis of skeletal system. Th e physio-
logical remodeling takes place during the healing of 
microscopic damage sites of bone tissue. Th ese dam-
age sites (about 500 μm in diameter) occur during 
normal physical activity and they are considered as a 
physiological phenomenon (13).
When the biomechanical conditions are altered, as 
in the case of the change of direction of transmission 
of bone forces, their form and size may change, and 
they are specifi c for each bone. Th e formation of 
bones, in physiological conditions, is limited to the 
periods of embryonic development and postnatal 
life, and it ends in the third decade of life. During 
the remodeling, the quantity of bone tissue is not 
changed, instead, the existing bone mass is rear-
ranged. About 25% of cancellous bone tissue and 
3% of compact bone tissue remodel per year (14). 
Th e purpose of bone remodeling is the adaptation 
of skeletal system to biomechanical circumstances 
throughout life, with the minimal quantity of bone 
material. If the strength of skeletal system depended 
on the increase of bone mass, the massive skeletal 
system would represent a burden to the organism. It 
is established that the fragility of neck of the femur 
in elderly women is not a consequence of bone mass 
loss but of inadequate remodeling of the existing 
bone mass (15).
MicroRNAs (miRNA) are a class of small, endoge-
nous, non-coding, single stranded RNAs. miRNAs 
are included in several developmental events during 
the embryogenesis and tissue homeostasis in adults. 
Epigenetically, miRNAs control gene expression 
through post-transcriptional regulation. Because the 
homeostasis of bone tissue is maintained through 
dynamic balance between osteoclast bone resorp-
tion and osteoblast bone formation, miRNAs are 
also important regulators of these processes. miR-
NAs may regulate osteogenesis and osteoclastogen-
esis positively or negatively, that is, miRNAs, target 
genes, intracellular eff ectors, and transcription fac-
tors aff ect homeostatic processes in bones (16).
NUTRITIONAL ASPECTS
Regarding the nutritional management of bone 
tissue diseases, existing evidence indicate the 
importance of nutrition quality and regular phys-
ical activity in order to ensure suffi  cient intake of 
proteins, calcium and vitamin D, which aff ect the 
pathogenesis of these diseases (17,18). At each stage 
of life, the dietary intake of the main bone nutrients, 
including calcium, vitamin D, and proteins contrib-
utes to the muscle and bone health, thereby decreas-
ing the risk of falls, osteoporosis, and fractures later 
in life (19).
Th ere is evidence that proteins from food directly 
infl uence key regulators of proteins and growth fac-
tors included in muscle and bone growth, such as 
rapamycin in mammals (mTOR) and insulin-like 
growth factor-I (IGF-I). Branched chain amino acids 
lead to the activation of mTOR and aromatic amino 
acids (which are especially represented in milk pro-
teins) and this further leads to increased IGF-I and 
results in greater muscle mass and strength (20,21). 
Daily protein intake is advised, and the quantities 
are similar for all adults, regardless of age; about 
0,8 g of proteins per kilogram of body mass each day 
(g/kg BW/d) (or 46-52  g/d) (22,23). Th e protein 
intake that represents 17-21% of total daily calories 
is recommended among adults of all ages (24).
Distribution of protein intake during the day may be 
important, and 20-25 g of dietary proteins per serv-
ing is proposed to allow proper stimulation of mus-
cle protein synthesis after meal, during the 24-hour 
period. Th e daily intake of proteins indirectly 
increases the level of circulating IGF-I, by improv-
ing renal production of 1,25(OH)2D3, which stim-
ulates intestinal absorption of calcium and inor-
ganic phosphate, and increases tubular reabsorption 
of inorganic phosphate. Th is indirectly aff ects bone 
mineralization. Dietary proteins infl uence mus-
cle anabolism through amino acids and IGF-I and 
indirectly aff ect muscle mass and strength. It was 
found that protein energy supplementation reduces 
the functional decline in weak elderly people and 
improves their physical activity (25,26).
CLINICAL ASPECTS
Elderly people who have osteoporotic hip fracture 
are often malnourished, especially in terms of pro-
tein intake, and insuffi  cient protein intake may con-
tribute to the occurrence of hip fracture. In a study 
on elderly people with a recent osteoporotic hip 
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fracture, protein supplementation was associated 
with increased serum IGF-I, decrease of bone loss of 
the proximal part of the femur, and shorter stay in 
rehabilitation hospitals (27). In a systematic review 
and meta-analysis, a positive association was found 
between protein intake and BMD, mineral compo-
sition of bones, and reduction of bone resorption 
markers (28). Th ere is evidence that diets rich in 
proteins and dairy products may help to reduce the 
loss of bone mass during weight loss. Proteins may 
help to preserve bone mass during weight loss by 
stimulating IGF-I and increasing intestinal calcium 
absorption (29).
Dietary protein intake is important for bones and 
muscles, and protein intake is in a positive correla-
tion with muscle mass and BMD in elderly people. 
Th e favorable eff ect of dietary proteins seems to be 
enhanced by simultaneous intake of foods that are 
metabolized to alkaline residues, such as fruits and 
vegetables (30).
A positive link between intake of dairy proteins and 
appendicular bone mineralization and muscle mass 
was found in elderly women (aged 80-92 years) (31). 
Dairy products including milk, yogurt, and cheese 
may represent an excellent food source of bone 
nutrients, since they provide a rich supply of cal-
cium, phosphorus, and high-quality proteins, with 
a relatively low cost (32,33).
Dairy products provide a package of essential nutri-
ents and it is diffi  cult to get those in low-dairy or 
dairy-free diets. For many people, it is impossible 
to achieve the recommended daily intake of cal-
cium with dairy-free diets. Th e recommended 
consumption is 3 servings of dairy products daily 
(for example, 1 glass of milk, 1 serving of cheese, 
1 yogurt), and this amount meets the recommended 
daily intake of calcium for general population. As 
for bone health, there is growing evidence that the 
eff ects of age-related or postmenopausal bone loss 
on the risk of fracture depend on the amount of 
bone mass achieved during childhood and ado-
lescence. It has been shown that adequate dietary 
intake of calcium and proteins is required to achieve 
optimal bone mass during skeletal growth and to 
prevent the loss of bone mass in elderly people. 
Current European Guide on Osteoporosis contains 
nutritive recommendations for bone health, includ-
ing at least 1000  mg/d of calcium and 800  IU/d 
of vitamin D. Available data show a positive asso-
ciation between dairy food intake and markers for 
bone health (i.e., bone mineral density and markers 
of bone remodeling) (34).
In spite of well-grounded benefi ts of dairy products 
for bone health, some people avoid these products 
in their diets due to the belief that dairy products 
may be harmful for health, especially in people hav-
ing a problem with weight, indigestion, arthritis, or 
in people trying to prevent cancer. Bioavailability of 
calcium from milk is high. In some people, digestion 
of milk causes gastrointestinal symptoms due to rel-
ative lack of lactase enzyme and undigested lactose is 
fermented by the intestinal bacteria. Self-diagnosis 
of lactose intolerance is common and often incor-
rect. In fact, the degree of lactose tolerance varies, 
and drastic restrictions are usually not necessary. 
Yogurts containing dissolved lactose and hard cheese 
that does not contain lactose are second-best sources 
of dietary calcium. In addition, some meta-analyses 
led to the conclusion that the restriction of dairy 
product intake is not reliable to help with a weight 
loss program. Th e data suggest that the consump-
tion of dairy products reduces body fat and preserves 
decreased body mass. Furthermore, recent data sug-
gest that consumption of dairy products protects 
from the risk of overweight and obesity. Studies on 
dairy products and arthritis are rare, nevertheless, 
previous research showed that no psychopathologi-
cal reason exist for the patients with osteoarthritis or 
rheumatoid arthritis to avoid consumption of dairy 
products. In relation to all of the above-mentioned 
indications, we may say that dairy product intake, 
in the recommended dose of 3 servings a day, is safe, 
practical, and approachable as part of balanced diet. 
Proven benefi ts of dairy products for bone health 
signifi cantly outweigh the possible, but unproven 
undesirable consequences (35).
In young women, consuming milk proteins after 
resistance exercises improves their anabolism. In 
addition, consuming milk proteins after resistance 
exercises has a positive eff ect on body composi-
tion by promoting fat loss, gain or maintenance of 
lean mass, and bone preservation. Nevertheless, an 
increase of BMD measured by densitometry, also 
called dual-energy x-ray absorptiometry (DEXA), 
may appear as artifacts of the measurement 
method (36,37).
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Cooper et al. conducted research on 900 pregnant 
women with a serum plasma 25-hydroxyvitamin D 
[25(OH)D] levels from 25-100 nmol/l at 12 weeks 
gestation. Th e pregnant women with similar base 
line levels of 25(OH)D were randomly assigned to 
group receiving 1000 international units (IU) chole-
calciferol/d or group receiving placebo until deliv-
ery. 25(OH)D was measured at 14 and 34  weeks 
of gestation. At 34  weeks gestation, the women 
in the treated group had a higher mean value of 
25(OH)D. Th e newborns were subjected to DEXA 
assessment of bone mass within 14 days from birth. 
Th e authors concluded that the prenatal supple-
ment of 1000  IU/d of cholecalciferol reduces the 
prevalence of vitamin D insuffi  ciency, and prevents 
gestational reduction of 25(OH)D in women who 
deliver in winter or spring (38).
Diet and exercise are important in preventing the 
reduction of muscles and bones. Vitamin D insuf-
fi ciency is associated with reduced muscle perfor-
mance and increased risks of fall, as well as increased 
rates of bone mass loss and fractures. Vitamin D 
plays a key role in the metabolism of calcium and 
phosphate and bone health. In the previous decade 
vitamin D was in focus of research, and besides its 
well-known role in calcium metabolism, the research 
revealed that the low levels of vitamin D are related 
to neurodegenerative disorders, cancer, altered glu-
cose metabolism and cardiovascular diseases. Th e 
link between vitamin D and many non-skeletal dis-
orders has directed the attention of researchers not 
only to elderly people, but also to younger popula-
tion, which seems to show a low circulating levels of 
25 (OH) D3 (39).
Th e supplementation caused an increase in myocyte 
cross-sectional area, through the activation of the 
vitamin D receptor in muscle tissue. In Europe, the 
recommended daily dose is 400 IU of vitamin D3 
for people older than 65  years (40). Numerous 
epidemiological studies showed that vitamin D 
defi ciency is present in over 50% of general pop-
ulation (41,42). A person can get smaller amount 
of vitamin D from low vitamin D food. However, 
for the most part, vitamin D is provided by syn-
thesis from provitamin D (7-dehydrocholesterol) 
in the skin, under the infl uence of sunlight. With 
age, the content of 7-dehydrocholesterol in the skin 
is reduced, making elderly people dependent on 
regular vitamin D intake through supplements. Th is 
is required for the adequate intestinal absorption of 
calcium (from food or pills) and for the prevention 
of hypocalcemia and secondary hyperparathyroid-
ism, which would inevitably lead to the loss of bone 
mass (3,6,13,16). In elderly people who have been 
regularly receiving vitamin D supplements, risk of 
fall and fracture is reduced, since vitamin D helps to 
maintain muscle strength and stability of walk (43).
CONCLUSION
Bone tissue is the major supporting tissue in human 
body, with a variety of dynamic functions, includ-
ing movement, protection of internal organs, and 
hematopoiesis. During life, the skeletal system is a 
subject to continuous transformation in order to 
maintain the optimal function of the main sup-
porting system in an adult organism. Th e balance 
between the processes of bone tissue formation and 
degradation is variable and is manifested in phys-
iological and pathological processes. About 25% 
of cancellous bone substance and 3% of compact 
bone substance are remodeled per year. Th e purpose 
of bone remodeling is adjusting the morphology 
of skeletal system to biomechanical circumstances 
during a lifetime, with minimal quantity of bone 
material. A  large number of studies indicate the 
importance of proper nutrition and regular physical 
activity, in order to ensure suffi  cient intake of pro-
teins, calcium and vitamin D, aiming at the preven-
tion of bone diseases. At each stage of life, adequate 
dietary intake of main bone nutrients contributes to 
muscle and bone health, thereby reducing the risk of 
falls, osteoporosis, and bone fracture.
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